Network intelligence for Lundbeck’s new drugs

January 2013. The success of its new drugs against alcohol abuse critically depends on the Danish drugmaker's capability to outbeat generics and more distinctive improvements than other branded therapeutics after market launch. Time is tight for Andreas Eggert and Barbara Jaszewski, his new colleague for global Pricing and Market Access.Reading time: 2 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section